Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose CD40 and CD40 ligand (CD40L) are costimulatory molecules of the tumor necrosis factor receptor superfamily and well known for their involvement in inflammatory diseases: atherosclerotic mouse models with disrupted CD40 signalling develop lesions of reduced size with a more stable plaque profile. This study investigated the potential of plasma and intraplaque levels of CD40 and CD40L as markers for cardiovascular disease (CVD) in humans and their association with plaque stability. Methods Soluble CD40 and CD40L (sCD40L) were measured in plasma in 1,437 subjects from The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT) cohort. Intra-plaque levels of sCD40 and sCD40L were measured in atherosclerotic plaque homogenates from 199 subjects of the Carotid Plaque Imaging Project (CPIP) cohort. Results Both plasma sCD40 and sCD40L levels were elevated in individuals with prevalent stroke, while sCD40 levels also were higher in individuals with a prior acute myocardial infarction. Plasma levels of sCD40 correlated with carotid intima-media thickness and total carotid plaque area and were associated with risk of cardiovascular events over a 3-year follow-up period. Intra-plaque levels of sCD40 and sCD40L were associated with plaque components characteristic for plaque vulnerability and extracellular matrix remodelling. Conclusions Higher plasma sCD40 and sCD40L levels are associated with prevalent CVD. Plasma sCD40 levels also correlate with the severity of carotid atherosclerosis and predict future cardiovascular events, while intra-plaque levels correlate with a vulnerable plaque phenotype. Our findings thus demonstrate that elevated levels of sCD40 and sCD40L are markers of CVD.
Abstract
Background and Purpose CD40 and CD40 ligand (CD40L) are costimulatory molecules of the tumor necrosis factor receptor superfamily and well known for their involvement in inflammatory diseases: atherosclerotic mouse models with disrupted CD40 signalling develop lesions of reduced size with a more stable plaque profile. This study investigated the potential of plasma and intraplaque levels of CD40 and CD40L as markers for cardiovascular disease (CVD) in humans and their association with plaque stability. Methods Soluble CD40 and CD40L (sCD40L) were measured in plasma in 1,437 subjects from The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT) cohort. Intra-plaque levels of sCD40 and sCD40L were measured in atherosclerotic plaque homogenates from 199 subjects of the Carotid Plaque Imaging Project (CPIP) cohort. Results Both plasma sCD40 and sCD40L levels were elevated in individuals with prevalent stroke, while sCD40 levels also were higher in individuals with a prior acute myocardial infarction. Plasma levels of sCD40 correlated with carotid intima-media thickness and total carotid plaque area and were associated with risk of cardiovascular events over a 3-year follow-up period. Intra-plaque levels of sCD40 and sCD40L were associated with plaque components characteristic for plaque vulnerability and extracellular matrix remodelling. Conclusions Higher plasma sCD40 and sCD40L levels are associated with prevalent CVD. Plasma sCD40 levels also correlate with the severity of carotid atherosclerosis and predict future cardiovascular events, while intra-plaque levels correlate with a vulnerable plaque phenotype. Our findings thus demonstrate that elevated levels of sCD40 and sCD40L are markers of CVD.
참고문헌 (12)
- Shore AC, "Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes : a European cross-sectional study", J Intern Med, 278, pp.291~302 (2015)
- Asciutto G, "Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques", Cardiovasc Pathol, 22, pp.438~443 (2013)
- Hansen F, "Accuracy of duplex sonography before carotid endarterectomy : a comparison with angiography", Eur J Vasc Endovasc Surg, 12, pp.331~336 (1996)
- Gonçalves I, "Changes related to age and cerebrovascular symptoms in the extracellular matrix of human carotid plaques", Stroke, 34, pp.616~622 (2003)
- Rattik S, "High plasma levels of heparin-binding epidermal growth factor are associated with a more stable plaque phenotype and reduced incidence of coronary events", Arterioscler Thromb Vasc Biol, 35, pp.222~228 (2015)
- Gonçalves I, "Elevated plasma levels of MMP-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes", Arterioscler Thromb Vasc Biol, 35, pp.1723~1731 (2015)
- Gonçalves I, "Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation", Arterioscler Thromb Vasc Biol, 32, pp.1505~1512 (2012)
- Edsfeldt A, "Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque", Stroke, 43, pp.3305~3312 (2012)
- Shami A, "Expression of fibromodulin in carotid atherosclerotic plaques is associated with diabetes and cerebrovascular events", Atherosclerosis, 241, pp.701~708 (2015)
- Dunér P, "Increased aldehyde-modification of collagen type IV in symptomatic plaques : a possible cause of endothelial dysfunction", Atherosclerosis, 240, pp.26~32 (2015)
- "Package ’rms’" (2021)[URL]
- Robin X, "pROC : an open-source package for R and S+ to analyze and compare ROC curves", BMC Bioinformatics, 12, pp.77~ (2011)